Description
Ondem md (Ondansetron ODT) 4 mg
Ondem md 4 mg contains ondansetron, an orally disintegrating tablet formulation of a selective serotonin 5-HT3 receptor antagonist. It is a prescription antiemetic used to help prevent nausea and vomiting in recognised clinical settings. The product name supplied is consistent with ondansetron ODT 4 mg, but the verified active ingredient is ondansetron.
Active Ingredient and Medicine Class
Ondansetron belongs to the 5-HT3 receptor antagonist class. It is available in orally disintegrating tablet form for oral use. The verified 4 mg strength matches the product information listed in prescribing resources.
Established Medical Uses
Official prescribing information identifies ondansetron orally disintegrating tablets for the prevention of nausea and vomiting associated with cancer chemotherapy, radiotherapy, and postoperative nausea and/or vomiting.
How It Works
Ondansetron works by blocking 5-HT3 serotonin receptors. These receptors participate in signalling pathways that can trigger nausea and vomiting, especially during chemotherapy, radiotherapy, and after surgery. By reducing this signalling, ondansetron helps prevent emetic symptoms.
Important Safety Information
Ondansetron is contraindicated in patients with known hypersensitivity to ondansetron or other selective 5-HT3 receptor antagonists, and it must not be used with apomorphine because of the risk of profound hypotension and loss of consciousness.
Important precautions include QT prolongation and reported cases of torsade de pointes; extra caution is advised in people with congenital long QT syndrome, electrolyte abnormalities, heart failure, bradyarrhythmias, or other medicines that prolong QT. Ondansetron has also been associated with serotonin syndrome when used with serotonergic medicines such as SSRIs, SNRIs, MAO inhibitors, tramadol, fentanyl, lithium, and intravenous methylene blue.
Other recognised precautions include possible myocardial ischemia and masking of progressive ileus or gastric distension in susceptible patients.
Possible Side Effects
Commonly reported adverse effects include headache, dizziness, constipation, and fatigue. More serious reactions can include hypersensitivity reactions, arrhythmias related to QT prolongation, serotonin syndrome, and myocardial ischemia.
Scientific Evidence
Peer-reviewed clinical studies support ondansetron’s antiemetic effect in postoperative nausea and vomiting and in chemotherapy-related settings. In a multicentre study of postoperative nausea and vomiting, oral ondansetron 4 mg improved complete response compared with placebo and was well tolerated. Other controlled studies have also shown benefit for prevention of postoperative nausea and vomiting.
Medical Information Notice
This educational summary is based on sources available at the time of review and does not replace the official patient leaflet, prescribing information, or individual assessment by a qualified healthcare professional.